Cargando…
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266011/ https://www.ncbi.nlm.nih.gov/pubmed/34268202 http://dx.doi.org/10.18502/ijph.v49iS1.3666 |
_version_ | 1783719851982848000 |
---|---|
author | SHEIKHSHAHROKH, Amirhossein RANJBAR, Reza SAEIDI, Elnaz SAFARPOOR DEHKORDI, Farhad HEIAT, Mohammad GHASEMI-DEHKORDI, Payam GOODARZI, Hamed |
author_facet | SHEIKHSHAHROKH, Amirhossein RANJBAR, Reza SAEIDI, Elnaz SAFARPOOR DEHKORDI, Farhad HEIAT, Mohammad GHASEMI-DEHKORDI, Payam GOODARZI, Hamed |
author_sort | SHEIKHSHAHROKH, Amirhossein |
collection | PubMed |
description | COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19). |
format | Online Article Text |
id | pubmed-8266011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-82660112021-07-14 Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review SHEIKHSHAHROKH, Amirhossein RANJBAR, Reza SAEIDI, Elnaz SAFARPOOR DEHKORDI, Farhad HEIAT, Mohammad GHASEMI-DEHKORDI, Payam GOODARZI, Hamed Iran J Public Health Review Article COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19). Tehran University of Medical Sciences 2020-10 /pmc/articles/PMC8266011/ /pubmed/34268202 http://dx.doi.org/10.18502/ijph.v49iS1.3666 Text en Copyright © 2020 Sheikhshahrokh et al. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Review Article SHEIKHSHAHROKH, Amirhossein RANJBAR, Reza SAEIDI, Elnaz SAFARPOOR DEHKORDI, Farhad HEIAT, Mohammad GHASEMI-DEHKORDI, Payam GOODARZI, Hamed Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
title | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
title_full | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
title_fullStr | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
title_full_unstemmed | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
title_short | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
title_sort | frontier therapeutics and vaccine strategies for sars-cov-2 (covid-19): a review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266011/ https://www.ncbi.nlm.nih.gov/pubmed/34268202 http://dx.doi.org/10.18502/ijph.v49iS1.3666 |
work_keys_str_mv | AT sheikhshahrokhamirhossein frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT ranjbarreza frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT saeidielnaz frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT safarpoordehkordifarhad frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT heiatmohammad frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT ghasemidehkordipayam frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT goodarzihamed frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview |